Abstract

Objective:

Corticosteroids are one of the treatment methods used to prevent inflammation in sepsis. This study aimed to determine the anti-inflammatory activity of astaxanthin in sepsis and compare it with dexamethasone.

Materials and Methods:

After approval of the local ethics committee, 40 Sprague-Dawley male rats were randomly assigned to the control group (n=8), lipopolysaccharide group (n=8), astaxanthin group (n=8), astaxanthin + lipopolysaccharide group (n=8) and dexamethasone + lipopolysaccharide group (n=8). On day 1, these groups were given dimethyl sulfoxide, Salmonella typhimurium lipopolysaccharide, astaxanthin dissolved in dimethyl sulfoxide, astaxanthin and lipopolysaccharide and dexamethasone and lipopolysaccharide, respectively. After 24 hours, rats underwent laparotomy, and liver and blood samples were taken. GraphPad Prism 6 was used for statistical analysis. P values less than 0.05 were considered significant.

Results:

Nuclear factor-kappa B levels in both treatment groups significantly decreased when compared with the lipopolysaccharide group. Apoptotic cells and reaction severity decreased significantly in the treatment groups compared with the lipopolysaccharide group.

Conclusion:

This study revealed that the use of astaxanthin had a positive effect on liver tissue undergoing treatment for sepsis. Moreover, despite some differences, measurement values were comparable when dexamethasone was administered.

Keywords: Astaxanthin, dexamethasone, anti-inflammatory, liver

References

  1. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A,et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:762-74.
  2. Zanotti-Cavazzoni SL, Dellinger RP, Parillo JE. Ciritical Care Medicine. In:Dellinger RP, Parillo JE, editors. Severe sepsis and Multiple Organ Dysfuction 4th ed. Philadephia Elsevier Saunders: 2014.p.365-78.
  3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
  4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
  5. Irwin RS, Rippe JM. Sepsis yönetimi (çeviri: S. Çakar Turhan). Tulunay M, Cuhruk H, editors. Yoğun Bakım Tıbbı. Ankara, Güneş tıp kitabevleri: 2014.p.1855-69.
  6. Zanotti S, Kumar A, Kumar A. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 2002;11:1061-75.
  7. Giamarellos-Bourboulis EJ, Routsi C, Plachouras D, Markaki V, Raftogiannis M, Zervakis D, et al. Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock? Crit Care 2006;10:R76.
  8. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005;174:5110-8.
  9. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-75.
  10. Li L, Whiteman M, Moore PK. Dexamethasone inhibits lipopolysaccharide-induced hydrogen sulphide biosynthesis in intact cells and in an animal model of endotoxic shock. J Cell Mol Med 2009;13:2684-92.
  11. Korhonen R, Lahti A, Hämäläinen M, Kankaanranta H, Moilanen E. Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages. Mol Pharmacol 2002;62:698-704.
  12. Lasa M, Brook M, Saklatvala J, Clark AR. Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol 2001;21:771-80.
  13. Ohgami K, Shiratori K, Kotake S, Nishida T, Mizuki N, Yazawa K, et al. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci 2003;44:2694-701.
  14. Otsuka T, Shimazawa M, Nakanishi T, Ohno Y, Inoue Y, Tsuruma K, et al. Protective effects of a dietary carotenoid, astaxanthin, against light-induced retinal damage. J Pharmacol Sci 2013;123:209-18.
  15. Uchiyama K, Naito Y, Hasegawa G, Nakamura N, Takahashi J, Yoshikawa T. Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep 2002;7:290-3.
  16. Lee SJ, Bai SK, Lee KS, Namkoong S, Na HJ, Ha KS, et al. Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells 2003;16:97-105.
  17. Franceschelli S, Pesce M, Ferrone A, De Lutiis MA, Patruno A, Grilli A, et al. Astaxanthin treatment confers protection against oxidative stress in U937 cells stimulated with lipopolysaccharide reducing O2- production. PLoS One 2014;9:e88359.
  18. Zhou L, Gao M, Xiao Z, Zhang J, Li X, Wang A. Protective effect of astaxanthin against multiple organ injury in a rat model of sepsis. J Surg Res 2015;195:559-67.
  19. Izumi-Nagai K, Nagai N, Ohgami K, Satofuka S, Ozawa Y, Tsubota K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci 2008;49:1679-85.
  20. Suzuki Y, Ohgami K, Shiratori K, Jin XH, Ilieva I, Koyama Y, et al. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res 2006;82:275-81.
  21. Zhang XS, Zhang X, Zhou ML, Zhou XM, Li N, Li W, et al. Amelioration of oxidative stress and protection against early brain injury by astaxanthin after experimental subarachnoid hemorrhage. J Neurosurg 2014;121:42-54.

How to cite?

1.
Çobaner N, Yelken B, Erkasap N, Özkurt M, Bektur E. Investigation of the Anti-inflammatory Effects of Astaxanthin on Liver Tissue in Lipopolysaccharide-induced Sepsis in Rats. Turk J Intensive Care. 2022;20(2):79-85. https://doi.org/10.4274/tybd.galenos.2021.52523